Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary

Orre, Maxine; Lotfi-Miri, Mozhgan; Mamers, Pamela; Rogers, Peter A. W.

doi:10.1038/bjc.1998.367

Cited by 54 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean microvessel count in different histological types was almost the same in our study, and moreover we did not find an evident difference concerning mucinous histotype such as happened in Orre et al [28] and Gasparini et al [22] studies.…”

Section: Discussionsupporting

confidence: 71%

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Ferrero¹,

Zola²,

Mazzola³

et al. 2004

Gynecologic Oncology

View full text Add to dashboard Cite

Objective. The primary aim of this study was to evaluate the prognostic and predictive value of pretreatment serum hemoglobin level (Hb) in advanced ovarian cancer; second aim was to perform a preliminary investigation of intratumoral microvessel density (IMD).Methods. The influence on survival and response to treatment of several clinico-pathological features, including Hb, was analyzed in 72 patients with advanced ovarian cancer. IMD was assessed in tumor specimens of 25 of the 72 patients to compare three different endothelial markers: anti-FactorVIII, anti-CD31 and anti-CD34. In this subgroup of patients, a preliminary analysis of the prognostic and predictive value of IMD, and its relationship with Hb and other clinico-pathological features, was performed.Results. Hb z 12 g/dl was significantly associated with a better overall survival in univariate analysis ( P = 0.0181) and was the only independent prognostic variable in multivariate analysis ( P = 0.0160). Hb was directly related to progression-free survival ( P = 0.0240) and complete response to treatment ( P = 0.016). In the preliminary investigation of IMD, mean microvessel count did not show any significant difference among the three endothelial markers used, but anti-CD34 revealed a more consistent staining reaction. The relationship between IMD and complete response to treatment was found near to statistical significance ( P = 0.05); Hb and IMD were inversely related (r = À0.47; P = 0.045).Conclusions. Hb has a prognostic and predictive value in advanced ovarian cancer. In our preliminary study, which was performed on a limited number of patients, we found anti-CD34 to be an optimal marker for IMD determination, IMD to be a possible predictive factor of complete response to treatment, and IMD and Hb to be inversely related. D

show abstract

Section: Discussionsupporting

confidence: 71%

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Ferrero¹,

Zola²,

Mazzola³

et al. 2004

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Published studies with blood vessel density in ovarian cancers are equivocal with some studies revealing an association with poor prognosis whereas others dispute this (Hollingsworth et al, 1995;Orre et al, 1998;Alvarez et al, 1999;Abulafia et al, 2000;Nakayama et al, 2001). We found that MVD in an overlapping set of tumours did not influence prognosis or survival or response to treatment.…”

Section: Discussioncontrasting

confidence: 47%

Role of lymphangiogenesis in epithelial ovarian cancer

et al. 2006

View full text Add to dashboard Cite

We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. The effect of prognostic variables on progression-free and overall survival was assessed. On multivariate analysis, bulky residual disease after surgery was the best prognostic indicator (Po0.001) for progression-free and overall survival (Po0.001). Lymphatic count was statistically significant as a prognostic factor for progression-free (P ¼ 0.05) and overall survival (P ¼ 0.04). However, lymphatic count did not impact on survival curves. No correlation was found between lymphatic count and age, histological subtype, FIGO stage or residual disease. Vascular count, VEGF or TP expressions were not significant in either analysis. Lymphatic spread may be significant in aiding metastases in ovarian cancer but requires other biological factors to act in conjunction, as it does not have clearcut prognostic significance. Dissemination of ovarian cancer does not occur primarily through vascular or lymphatic routes but may occur through direct intraperitoneal spread of disease.

show abstract

“…The role of angiogenesis in ovarian carcinoma development remains unclear; there are contradictory studies with regard to the influence of microvessel density in ovarian cancer prognosis (5,25,26). Immunohistochemical assessment of VEGF within a tumor offers further information about the potential for angiogenic activity and its effects on tumor behavior and subsequent prognosis for the patient.…”

Section: Discussionmentioning

confidence: 99%

Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?

Duncan

Al‐Attar

Rolland

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Angiogenesis has a vital role in tumor growth and metastasis, and vascular endothelial growth factor (VEGF) represents a potent cytokine in this process. However, the influence of VEGF in ovarian cancer remains controversial. Interest has focused on the use of antiangiogenic drugs in ovarian cancer. This study aims to establish the pattern of expression and effect on prognosis of VEGF in a large population of ovarian cancer patients and to potentially identify a cohort in whom antiangiogenic therapy is appropriate. Experimental Design: Using a tissue microarray of 339 primary ovarian cancers, the expression of VEGF was assessed immunohistochemically. Coupled to a comprehensive database of clinicopathologic variables, its effect on these factors and survival was studied. Results: Tumors expressing high levels of VEGF had significantly poorer survival (P = 0.04). Factors shown to predict prognosis independently of each other were age, International Federation of Gynecologists and Obstetricians stage, and the absence of macroscopic disease after surgery. VEGF was independently predictive of prognosis on multivariate analysis (P = 0.02). There was no correlation between VEGF and any clinicopathologic variable. High expression of VEGF was seen in only 7% of the tumors, suggesting that the role of antiangiogenic drugs may be limited to a small subset of patients. Conclusion: High VEGF expression occurs in a small proportion of ovarian cancers, and this independently predicts poor prognosis. The small percentage of tumors with high levels of VEGF activity suggests that the role of bevacizumab may potentially be limited to a few patients; these patients could be targeted by molecular profiling.

show abstract

Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary

Cited by 54 publications

References 19 publications

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Role of lymphangiogenesis in epithelial ovarian cancer

Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?

Contact Info

Product

Resources

About